A detailed history of Sjs Investment Consulting Inc. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Sjs Investment Consulting Inc. holds 185 shares of ARQT stock, worth $1,883. This represents 0.0% of its overall portfolio holdings.

Number of Shares
185
Holding current value
$1,883
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

BUY
$8.32 - $11.0 $1,539 - $2,035
185 New
185 $1,000

Others Institutions Holding ARQT

About Arcutis Biotherapeutics, Inc.


  • Ticker ARQT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,187,500
  • Market Cap $613M
  • Description
  • Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...
More about ARQT
Track This Portfolio

Track Sjs Investment Consulting Inc. Portfolio

Follow Sjs Investment Consulting Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sjs Investment Consulting Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sjs Investment Consulting Inc. with notifications on news.